Core Viewpoint - DaVita Inc. reported a decline in adjusted earnings per share (EPS) for Q3 2024, missing consensus estimates, despite an increase in revenues driven by higher reimbursement rates and other fluctuations [1][2][9][10]. Financial Performance - Adjusted EPS for Q3 2024 was $2.59, down 9.1% year over year, and missed the Zacks Consensus Estimate by 6.2% [1] - GAAP EPS for the quarter was $2.50, reflecting a decline of 4.6% year over year [1] - Revenues reached $3.26 billion, an increase of 4.6% year over year, surpassing the Zacks Consensus Estimate by 1.3% [2] - Gross profit rose 5.5% year over year to $1.11 billion, with a gross margin of 34.1%, expanding by 30 basis points [6] Revenue Breakdown - Dialysis patient service revenues were $3.14 billion, up 6.3% year over year [3] - Other revenues were $125 million, down 26.2% from the previous year [3] Operational Metrics - Total U.S. dialysis treatments for Q3 were 7,350,784, averaging 93,048 per day, which is a sequential decrease of 0.1% [4] - DaVita served approximately 265,400 patients at 3,113 outpatient dialysis centers as of September 30, 2024 [4] Strategic Developments - During Q3 2024, DaVita opened three and closed 15 dialysis centers in the U.S., while also acquiring one and opening four centers outside the U.S. [5] - The company had around 69,500 patients in risk-based integrated care arrangements, representing $5.4 billion in annualized medical spend [5] Margin and Cost Analysis - Adjusted operating profit totaled $718.2 million, reflecting a 6.1% increase from the prior year [6] - General & administrative expenses increased by 4.4% year over year to $393.5 million [6] Financial Position - DaVita ended Q3 2024 with cash and cash equivalents of $1.09 billion, up from $437.2 million at the end of Q2 [7] - Total debt at the end of Q3 was $9.56 billion, compared to $8.99 billion at the end of Q2 [7] - Cumulative net cash provided by operating activities was $1.47 billion, down from $1.57 billion a year ago [7] Future Outlook - DaVita reiterated its adjusted EPS guidance for 2024, projecting a range of $9.25-$10.05, with the Zacks Consensus Estimate at $9.99 [8]

DaVita Inc. (NYSE:DVA) Q3 2024 Earnings Conference Call October 29, 2024 5:00 PM ET Company Participants Nic Eliason - Group Vice President, Investor Relations Javier Rodriguez - Chief Executive Officer Joel Ackerman - Chief Financial Officer Conference Call Participants Andrew Mok - Barclays AJ Rice - UBS Pito Chickering - Deutsche Bank Lisa Clive - Bernstein Joanna Gajuk - Bank of America Ryan Langston - TD Cowen Justin Lake - Wolfe Research Operator Good evening. My name is Michelle and I will be your co ...

DaVita HealthCare (DVA) came out with quarterly earnings of $2.59 per share, missing the Zacks Consensus Estimate of $2.76 per share. This compares to earnings of $2.85 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.16%. A quarter ago, it was expected that this kidney dialysis provider would post earnings of $2.47 per share when it actually produced earnings of $2.59, delivering a surprise of 4.86%.Over the last four quart ...

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |---------------------------------------------------------------------|-------------------------------------------|-------------------------------| | For the | transition per ...

Contact: Investor Relations DaVita Inc. ir@davita.com DaVita Inc. 3rd Quarter 2024 Results Denver, Colorado, October 29, 2024 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2024. "We continue to provide quality care for our patients across the continuum of care, while delivering solid third quarter financial performance," said Javier Rodriguez, CEO of DaVita Inc. "And, in light of recent severe storms, I am grateful for the remarkable resilience of ou ...

DENVER, Oct. 29, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2024. "We continue to provide quality care for our patients across the continuum of care, while delivering solid third quarter financial performance," said Javier Rodriguez, CEO of DaVita Inc. "And, in light of recent severe storms, I am grateful for the remarkable resilience of our patients and our frontline caregivers." Financial and operating highlights for the quart ...

DaVita Inc. (DVA) is scheduled to report third-quarter 2024 results on Oct. 29, after the closing bell.In the last reported quarter, the company’s earnings per share (EPS) of $2.59 surpassed the Zacks Consensus Estimate by 4.9%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, delivering an earnings surprise of 24.2%, on average.For third-quarter 2024, the Zacks Consensus Estimate for revenues is pegged at $3.22 billion, implying an improvement of 3.2 ...

DENVER and SAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- DaVita Clinical Research (DCR), a leading innovator in kidney care research and wholly owned subsidiary of DaVita Inc., will present the results of five innovative research projects at the American Society of Nephrology (ASN)'s annual Kidney Week meeting, which is currently underway in San Diego, CA. With a focus on improving racial equity in transplantation and key measures of clinical quality such as hospitalizations, DCR works to tackle pressing issues ...

In the latest market close, DaVita HealthCare (DVA) reached $163.16, with a +1% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 0.05%. Meanwhile, the Dow experienced a drop of 0.02%, and the technology-dominated Nasdaq saw an increase of 0.18%.The kidney dialysis provider's shares have seen a decrease of 0.02% over the last month, surpassing the Medical sector's loss of 4.16% and falling behind the S&P 500's gain of 2.76%.Investors will be eagerly watching for the perfo ...

Nephrologists drive transformative outcomes through government's coordinated care program serving high-need patientsDENVER, Oct. 22, 2024 /PRNewswire/ -- DaVita today announced performance year one clinical outcomes achieved in partnership with nearly 1,300 nephrologists across the U.S. through value-based care arrangements designed to enhance the lives of Medicare patients with kidney disease. As the broader health care community continues to explore value-based care arrangements to improve health outcomes ...